https://sms.carm.es/ricsmur/handle/123456789/17146 2026-05-26T11:59:33Z 2026-05-26T11:59:33Z Espert, R Gadea, M Alino, M Oltra-Cucarella, Javier Perpina, C https://sms.carm.es/ricsmur/handle/123456789/26530 2026-05-13T11:04:53Z 2018-03-01T00:00:00Z

Enfermedad de moyamoya: aspectos clínicos, neurorradiológicos, neuropsicolológicos y genéticos Espert, R; Gadea, M; Alino, M; Oltra-Cucarella, Javier; Perpina, C INTRODUCTION: Moyamoya disease (MMD) is an occlusive cerebrovascular disease characterized by progressive stenosis or occlusion in the terminal portion of the bilateral internal carotid arteries, affecting both children and adults. AIM: To conduct a review and update on MMD from a clinical, neuroradiological, neuropsychological and genetic perspective. DEVELOPMENT: In this pathology, which occurs with ischemia or cerebral hemorrhage, an unusual compensatory vascular network (moyamoya vessels) develops at the base of the brain in the form of collateral channels. MMD can present clinically with hemiparesis, dysarthria, aphasia, headache, seizures, visual deficits, syncopes or changes in personality. At the neuropsychological level, and even in the absence of obvious strokes, patients usually present impairment of attention, memory, behavior and executive functions. High resolution angiography and magnetic resonance imaging have been a neuroradiological advance towards an early detection of this disease. At the genetic level, the RING (really interesting new gene) RNF213 has recently been identified, and it is considered the most important genetic risk factor known up to now in the MMD. CONCLUSIONS: MMD is a rare pathology that predominantly affects the frontal lobes. The genetic and neuroradiological advances, in addition to a cognitive profile, contribute to early diagnosis and treatment to improve the quality of life of these patients.

2018-03-01T00:00:00Z Duque, Pablo Oltra-Cucarella, Javier Fernández, Óscar Sepulcre, Jorge https://sms.carm.es/ricsmur/handle/123456789/26522 2026-05-13T11:04:49Z 2017-01-01T00:00:00Z

Batería neuropsicológica breve en la esclerosis múltiple. Baremación normativa estratificada por edad y nivel educativo Duque, Pablo; Oltra-Cucarella, Javier; Fernández, Óscar; Sepulcre, Jorge INTRODUCTION: Interpretation of the performance on cognitive tests for neuropsychological assessment in multiple sclerosis (MS) differs according to the educational level of the examinee. AIMS: To provide normative data for the Brief Neuropsychological Battery (BNB) for MS stratified by age and education, as well as to demonstrate the utility of the battery for discriminating between healthy controls and patients with MS. SUBJECTS AND METHODS: Data from 701 healthy volunteers from the original normative sample were stratified by age and education using regression analyses of standard scores. Performance of the healthy control group was compared to a group of 112 patients with MS. RESULTS: Significant differences on the BNB were found between groups, mainly in tasks of information processing speed, working memory and verbal memory. Age and sex variables did not have a significant effect on the results. CONCLUSIONS: Our data indicate that the BNB for MS is sensitive for identifying cognitive impairments in MS, specifically in tasks measuring working memory.

2017-01-01T00:00:00Z López-Santiago, Asensio https://sms.carm.es/ricsmur/handle/123456789/26509 2026-05-13T11:02:49Z 2024-11-01T00:00:00Z

¿A quién le importa la prevención? López-Santiago, Asensio

2024-11-01T00:00:00Z Conesa-Nicolás, Elena García-Lagunar, María-Henar Núñez-Bracamonte, Sara García-Simón, María-Sergia Mira-Sirvent, María-del-Carmen https://sms.carm.es/ricsmur/handle/123456789/26490 2026-05-13T11:04:52Z 2020-12-31T00:00:00Z

Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis Conesa-Nicolás, Elena; García-Lagunar, María-Henar; Núñez-Bracamonte, Sara; García-Simón, María-Sergia; Mira-Sirvent, María-del-Carmen OBJECTIVE: To determine persistence of treatment with secukinumab across its different indications. METHOD: This is a retrospective descriptive observational study including adult patients treated with secukinumab in its different  indications from the drug's introduction in November 2015 to October  2019. The variables included were sex; age; diagnosis; initiation date; line of treatment; number of patients who discontinued treatment and reason  for discontinuation; overall persistence at 12 months; distribution of  patients; and persistence according to indication, line of treatment and  reason for suspension. RESULTS: One-hundred forty-three patients were started on secukinumab, but only patients who had been in treatment at least 12  months before the end of the study were included. Mean patient age was  49.8 years (±12.6); 52.9% were men. Fifty-six patients (53.8%) had  discontinued treatment by the end of the study, with a mean duration of  treatment of 12.7 months (±10.2). The other patients (n = 48) continued  with their therapy. Mean duration of treatment in these patients was 25.7  months (±9.9). Overall persistence at 12 months was 10.0 months (±3.3)  with a discontinuation rate at 12 months of 31.7%. Persistence at 12  months was 10.7 months (±2.9) for patients with psoriasis, 9.7 months  (±3.4) for patients with psoriatic arthritis, and 8.8 months (±3.8) for  those with ankylosing spondylitis. Of the 48 patients who continued with  their treatment after completion of the study, 22 (45.8%) received the  drug as first-line treatment. Of the 56 discontinuations, 15 (26.8%) were  due to primary failure (persistence:  3.8 months [±1.1]) and 27 (48.2%)  were due to secondary failure (persistence: 18.6 months [±9.6]).  Persistence in patients who continued treatment was higher in psoriasis  (28.8 months [±10.3]). In those who discontinued due to secondary  failure it was higher in the group with ankylosing spondylitis (28.0 months  [±4.2]). Persistence among patients on first-line secukinumab was higher  than for other patients: 21.2 months (±7.2) if they stayed on treatment,  3.5 months (±0.5) if they presented with primary treatment failure, and  8.3 months (±2.5) in those with secondary treatment failure. CONCLUSIONS: Our data show slightly higher persistence levels in patients with psoriasis and lower discontinuation rates in those without  previous exposure to biological therapy. Long-term studies are needed to  confirm these findings and to gain a better understanding of the factors  that can influence persistence of secukinumab.

2020-12-31T00:00:00Z